27.8% growth masks generic stagnation; capex ramp ahead

Delivered 27.8% YoY, but constant currency 10%; Custom Synthesis 60% mix-aided

Nutraceutical 19% YoY, but overall generics volume flat despite price increases (solvent cost pass-through)

68% gross margin this quarter, but analyst-adjusted for ₹300-400 Cr inventory build yields 55-58%; margins lumpy

70% capitalized, validations ongoing; timelines uncertain (regulatory approvals in customer's hands)

Expanding SPPS capacity, multiple fragments in validation, but no revenue breakout disclosed

60% vs historical ~50%; driven by validation batch shipments. Management cautioned lumpiness; near-term Commercial ramp depends on regulatory approvals.

Despite 27.8% total revenue growth, generic volume stable (nutraceutical +19% masks underlying); pricing gains offset by cost inflation, not demand.

Gross margin 68% this quarter but management emphasized lumpiness, year-on-year ~60% historical. Solvent costs 'double/triple,' inventory build temporary. No margin target raised; guidance maintained.

70% of ₹2000 Cr capitalized (~₹1400 Cr), validations ongoing. No delay flagged. Timelines depend on customer regulatory approvals (external).

Depends on product; some <1000 kg annual demand, others 5000-6000 tonnes. Can't generalize. Bound by CDAs on quantities and order book.

Divi's unique — only player with complete backward integration from raw materials. Many fragment opportunities in pipeline, clinical phases. Expanding SPPS capacity.

Part of innovator CMC filing. Regulatory clearances required. We're ready for inspection anytime. Clarity on timelines when customer files; FDA approval timing unknown.

Solvent costs elevated, forex loss ₹7 Cr this quarter vs ₹39 Cr gain last year. Look at year-on-year, not quarterly. Margins lumpy. CS 60% this quarter, slightly higher than Q4. Full-year guidance: similar EBITDA to last year.

Stocking on 3-month rolling basis for supply security (solvent availability, West Asia risk). Decision made in March to avoid production stoppage. Will continue till macro uncertainty persists.

Solvent doubled/tripled, cost-based pricing to customers. This is market correction on raw materials, not pricing recovery. Volume 'stable' — no demand improvement signal. Per-product calculation; can't generalize across 60 products.

Stick to double-digit growth assurance. Lumpiness; can't predict 60-40 or 50-50 next month. Depends on regulatory approvals. Want healthy mix; regulatory timelines ifs.

Difficult to say; price differs per product. Organization looks at double-digit growth. Want good product mix, avoid heaviness on one product/customer/supply chain.

About 70% capitalized; total ₹2000 Cr declared earlier. So ~₹1400 Cr spent so far.

Can't disclose GLP-1 or small molecule splits (CDAs). Validations of 3 large projects done, several other projects in pipeline. Peptide key portfolio, growing strongly; fragments being validated/supplied; expanding SPPS capacity.

Largest integrated player = backward integrated from raw materials, protected amino acids, resins, FMOC/BOC, tags. Competitive edge; supply + faster delivery. Complementary to customers, not competitive.

Few weeks flat, then rise again. Depends on Middle East news daily. Supply not easily available; proactive 3-month rolling stocking prevents stoppage but expensive.

Can't comment unit-by-unit; across all 3 units, 80-85% utilization.

No inventory gains.

Gross margin ~60% all year. EBITDA margin similar to last year. This quarter ~68% gross but not consistent; lumpiness. Depends on validation approvals = higher CS %, better margins.

Iodine: signing long-term contracts with 2 customers. One already commercialized; second in next few months, substantial quantities. Gadolinium: still in clinical Phase II/III, slow phase. Waiting for regulatory approvals.

Several projects in pipeline. ~18-20 projects commercialized or being commercialized. Can't disclose due to CDAs.

Divi's has 30-year track record, one of first CDMOs in India. Customers value sustainability, EHS, safety, not just pricing. Customer relationships built on history and trust.

Don't disclose product-wise information.

Three major capex projects = three different products. Other projects also validated; can't disclose much. Several projects going to individual molecules attaining patient population.

Combination of validation production volume, intermediates, WIP, finished goods + material price inflation. Difficult to predict due to Middle East macro; if ceasefire, costs/volumes normalize. Depends on factors out of control.

Reiterated multiple times despite Q1 mix lumpiness. Constant currency 10%; nominal 27.8% Q1. Dependent on validation/regulatory approval ramps.

FY26 EBITDA margin ~37% implied. Q1 68% gross but called 'lumpy'; no margin expansion signaled despite capex ramp. Hedged on lumpiness.

On track. Validations ongoing. Remaining ~₹600 Cr to complete. Unit-3 expansion also ongoing. Timing dependent on regulatory approvals and customer requirements.

Three major capex projects require customer regulatory filings and FDA/agency approvals. No direct control; timelines 1-2 years typical post-validation. Delays cascade to commercial ramp.

Solvent costs doubled/tripled due to West Asia disruptions. Not supply-constrained currently but expensive. Strategic 3-month inventory build (₹500 Cr+ impact) necessary to avoid stoppage; margins compressed.

Generic volumes described as 'stable' but flat YoY. 10% price hikes are cost pass-through (solvent), not market recovery. Underlying demand not growing; pricing power limited to offsetting inflation.

90% exports; 27.8% nominal growth overstates underlying ₹ business (constant currency 10%). Net forex loss ₹7 Cr Q1 FY27 vs ₹39 Cr gain Q1 FY26 = ₹46 Cr adverse swing. INR appreciation risk to forward guidance.

₹1400 Cr+ remaining to spend on 3 projects. Validations depend on customer schedules, regulatory approval timing external. CWIP ₹2034 Cr is not yet productive capacity.

₹500 Cr inventory build (vs ₹50-100 Cr historical run-rate) temporary due to West Asia macro uncertainty. If macro stabilizes, inventory reverses, hitting OPM in Q2/Q3 by ₹300-400 Cr swing.